AUPH vs TAK vs BMY Stock Comparison

Aurinia Pharmaceuticals, Takeda Pharmaceutical and Bristol Myers Squibb Prices as of Oct 28, 2026 Peers: Industry group
BMY Bristol Myers Squibb Co
$60.61 -5.1% 1M +41.5% 1Y
Market cap
$123.81B
P/E
13.3x
Revenue (TTM)
$49.19B
Div. yield
4.16%
Pharmaceuticals Healthcare
3 wins

Head to Head

12 decided of 12

Takeda Pharmaceutical leads on 5 of the 12 questions below (Takeda Pharmaceutical 5, Aurinia Pharmaceuticals 4, Bristol Myers Squibb 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAUPHTAKBMYLeader
Larger companyMarket capitalisation $2.31B $64.13B $123.81B BMY
Cheaper on earningsLower P/E, profitable companies only 7.2x 110.5x 13.3x AUPH
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.1x 50.4x 9.1x BMY
Faster revenue growthRevenue growth, trailing twelve months +19.8% +0.7% +3.1% AUPH
More profitableNet margin, trailing twelve months 100.8% 1.2% 18.9% AUPH
Better return on capitalReturn on invested capital — 3.5% -3.3% TAK
Less leveragedLower net debt / EBITDA — 3.5x 78.9x TAK
Higher dividend yieldTrailing dividend yield — 1.54% 4.16% BMY
Better 1-year returnPrice return, last 12 months +37.5% +42.9% +41.5% TAK
Better 5-year returnAnnualised price return, 5 years -12.1%/yr +7.5%/yr +0.7%/yr TAK
Less volatileAnnualised volatility, 1 year 37.2% 21.5% 28.4% TAK
Higher overall scoreMean of the five percentile scores vs peers 90/100 62/100 66/100 AUPH

Percentile Scorecard

AUPHTAKBMY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAUPHTAKBMY
Valuation 93 #45 of 625 98 #16 of 625 86 #88 of 625
Growth 96 #26 of 602 21 #476 of 602 53 #286 of 602
Profitability 97 #17 of 549 85 #82 of 549 87 #71 of 549
Financial Health 74 #172 of 654 34 #430 of 654 16 #552 of 654
Shareholder Returns 92 #31 of 367 74 #98 of 367 88 #44 of 367
Overall 90 62 66
  • AUPH ranked among 672 companies in Pharmaceuticals and Biotechnology
  • TAK ranked among 672 companies in Pharmaceuticals and Biotechnology
  • BMY ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAUPHTAKBMYSPY
1 month +5.1%+6.6%-5.1% +0.9%
3 months +14.4%+13.5%-4.0% +5.9%
6 months +13.6%+23.6%+5.2% +8.5%
Year to date +8.8%+29.2%+12.4% +13.3%
1 year +37.5%+42.9%+41.5% +12.4%
3 years +141.4%+49.6%+18.8% +88.1%
3 years, per year +34.2%+14.4%+5.9% +23.5%
5 years -47.5%+43.7%+3.8% +68.2%
5 years, per year -12.1%+7.5%+0.7% +11.0%
10 years +437.5%-12.4%+18.8% +263.4%
10 years, per year +18.3%-1.3%+1.7% +13.8%

Risk

MeasureAUPHTAKBMYSPY
Volatility, 1Y 37.2%21.5%28.4% 12.7%
Downside volatility, 1Y 34.0%20.2%25.5% 12.7%
Beta vs S&P 500, 1Y 0.540.110.20 1.00
Return / volatility, 1Y 1.011.991.46 0.98
Max drawdown, 5Y -87.6%-26.4%-51.1% -25.4%
From 52-week high -6.8%-1.4%-11.0% -0.9%
52-week high $18.62$20.43$68.09 $779.14
52-week low $12.12$13.23$42.60 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAUPHTAKBMY
P/E now vs peer median 7.2xmedian 17.4x 110.5xmedian 17.4x 13.3xmedian 17.4x
P/S now vs peer median 7.4xmedian 9.1x 1.4xmedian 9.1x 2.5xmedian 9.1x
EV/EBITDA now vs peer median 11.0xmedian 17.1x 12.3xmedian 17.1x 383.9xmedian 17.1x
P/FCF now vs peer median 13.2xmedian 19.0x 12.3xmedian 19.0x 10.8xmedian 19.0x
P/B now vs peer median 3.8xmedian 2.2x 1.4xmedian 2.2x 5.5xmedian 2.2x
PEG now vs peer median 0.08median 0.34 -2.72median 0.34 2.17median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAUPHTAKBMY
Revenue $311.51M $46.49B $49.19B
Gross profit $281.47M $30.58B $34.51B
Operating income $150.75M $2.71B -$2.77B
Net income $314.11M -$1.04B $9.28B
Free cash flow $175.07M $5.20B $11.44B
R&D $39.85M $4.53B $10.72B
EPS (diluted) $2.35 $0.18 $4.53
Cash & equivalents $179.83M $2.85B $8.72B
Total debt – $126.30B $43.12B
Shares (diluted) 133.53M 3.15B 2.05B
Enterprise value $735.55M $40.50B $75.08B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAUPHTAKBMY
P/E 7.2x 110.5x 13.3x
P/FCF 13.2x 12.3x 10.8x
P/Operating cash flow 13.2x 10.2x 9.7x
P/S 7.4x 1.4x 2.5x
P/B 3.8x 1.4x 5.5x
P/Tangible book 3.8x 2.5x 25.1x
EV/EBITDA 11.0x 12.3x 383.9x
EV/EBIT 12.4x 33.0x -56.3x
EV/Revenue 6.0x 1.9x 3.2x
EV/FCF 10.6x 17.2x 13.6x
EV/Operating cash flow 10.6x 14.3x 12.2x
PEG (3Y EPS CAGR) 0.08 -2.72 2.17

Growth

14 metrics
MetricAUPHTAKBMY
Revenue growth (1Y) 19.8% 0.7% 3.1%
Revenue CAGR (3Y) 24.8% 14.8% 2.9%
Gross profit growth (1Y) 20.9% -0.8% 2.9%
Gross profit CAGR (3Y) 22.2% -0.2% -0.3%
Operating income growth (1Y) 189.8% -43.4% 63.5%
Operating income CAGR (3Y) 56.2% -14.3% -17.9%
Net income growth (1Y) 418.0% -209.1% 83.3%
Net income CAGR (3Y) 84.9% -35.3% 5.2%
EPS growth (1Y) 433.5% -75.7% 82.9%
EPS CAGR (3Y) 87.7% -40.6% 6.2%
Operating cash flow growth (1Y) 89.1% -14.8% -19.6%
Operating cash flow CAGR (3Y) 86.1% -4.4% 2.6%
Free cash flow growth (1Y) 89.4% -13.3% -21.5%
Free cash flow CAGR (3Y) 85.3% -5.2% 2.2%

Profitability

14 metrics
MetricAUPHTAKBMY
Gross margin 90.4% 65.8% 70.2%
EBITDA margin 54.6% 15.6% 0.8%
Operating margin 48.4% 5.8% -5.6%
Pretax margin 51.5% 2.6% 24.2%
Net margin 100.8% 1.2% 18.9%
FCF margin 56.2% 11.2% 23.3%
Operating cash flow margin 56.3% 13.5% 26.0%
Return on equity 53.1% 1.2% 43.7%
Return on assets 41.4% 0.6% 10.7%
Return on invested capital – 3.5% -3.3%
Return on capital employed 22.9% 3.0% -4.0%
Asset turnover 0.4x 0.5x 0.6x
Cash conversion (OCF / net income) 0.6x -6.0x 1.4x
Stock comp / revenue 4.7% 1.0% 1.1%

Financial Health

11 metrics
MetricAUPHTAKBMY
Debt / assets – 32.0% 49.2%
Debt / equity – 0.7x 1.9x
Net debt / EBITDA – 3.5x 78.9x
Debt / FCF – 6.0x 3.8x
Liabilities / assets 22.4% 51.7% 74.5%
Equity / assets 77.6% 48.3% 25.5%
Interest coverage 36.7x 0.8x –
Current ratio 5.4x 3.2x 1.5x
Quick ratio 4.8x 1.9x 1.2x
Cash ratio 4.4x 0.9x 0.6x
Altman Z-score 8.47 1.57 2.05

Shareholder Returns

7 metrics
MetricAUPHTAKBMY
Dividend yield – 1.5% 4.2%
Net buyback yield 0.9% 1.0% –
Shareholder yield 0.9% 2.6% 4.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAUPHTAKBMY
Forward P/E 18.1xFY2026 50.4xFY2026 9.1xFY2026
EPS, next fiscal year $0.96FY2026 $0.40FY2026 $6.63FY2026
EPS growth, next FY -53.6%FY2026 +5.3%FY2026 +7.8%FY2026
EPS growth, the year after +14.6% +62.5% -3.9%
Revenue, next fiscal year $348.13MFY2026 $28.27BFY2026 $52.09BFY2026
Revenue growth, next FY +23.0%FY2026 -0.8%FY2026 +8.1%FY2026
Revenue growth, the year after +6.9% +11.9% -9.3%
AUPH estimates →TAK estimates →BMY estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAUPHTAKBMY
Held by institutions 58.7% 3.3% 81.8%
Institutions holding 280 378 2,520
Change in shares held, QoQ +5.4% +6.2% +3.8%
Institutions buying 156 212 1,186
Institutions selling 78 98 986
Buyers to sellers 2.00 2.16 1.20
AUPH holders →TAK holders →BMY holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AUPHTAKBMY
AUPH 1.00 0.18 0.12
TAK 0.18 1.00 0.34
BMY 0.12 0.34 1.00

Add a Peer

Largest companies in the same industry
AUPH · Pharmaceuticals
+LLYEli Lilly +JNJJohnson & Johnson +ABBVAbbVie +MRKMerck +NVSNovartis Ag +AZNAstrazeneca +PFEPfizer +GSKGsk
Plot all 237 Pharmaceuticals stocks →

Related Comparisons

AUPH vs LLYEli Lilly AUPH vs JNJJohnson & Johnson AUPH vs ABBVAbbVie AUPH vs MRKMerck

Frequently Asked Questions

Which is bigger, AUPH, TAK and BMY?

Bristol Myers Squibb (BMY) is the largest by market capitalisation: Aurinia Pharmaceuticals (AUPH) $2.31B, Takeda Pharmaceutical (TAK) $64.13B, Bristol Myers Squibb (BMY) $123.81B.

Which stock is cheaper, AUPH, TAK and BMY?

Aurinia Pharmaceuticals (AUPH) trades on the lowest price-to-earnings ratio (Aurinia Pharmaceuticals (AUPH) 7.2x, Takeda Pharmaceutical (TAK) 110.5x, Bristol Myers Squibb (BMY) 13.3x). On next year's consensus earnings, Bristol Myers Squibb (BMY) is cheapest (Aurinia Pharmaceuticals (AUPH) 18.1x, Takeda Pharmaceutical (TAK) 50.4x, Bristol Myers Squibb (BMY) 9.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Aurinia Pharmaceuticals (AUPH) grew revenue fastest over the trailing twelve months: Aurinia Pharmaceuticals (AUPH) +19.8%, Takeda Pharmaceutical (TAK) +0.7%, Bristol Myers Squibb (BMY) +3.1%.

Which company is more profitable?

Aurinia Pharmaceuticals (AUPH) has the highest net margin (Aurinia Pharmaceuticals (AUPH) 100.8%, Takeda Pharmaceutical (TAK) 1.2%, Bristol Myers Squibb (BMY) 18.9%). On return on invested capital, Takeda Pharmaceutical (TAK) leads (Takeda Pharmaceutical (TAK) 3.5%, Bristol Myers Squibb (BMY) -3.3%).

Which stock has performed better?

Over the past year Takeda Pharmaceutical (TAK) returned the most: Aurinia Pharmaceuticals (AUPH) +37.5%, Takeda Pharmaceutical (TAK) +42.9%, Bristol Myers Squibb (BMY) +41.5%. Over five years, Takeda Pharmaceutical (TAK) compounded fastest (Aurinia Pharmaceuticals (AUPH) -12.1%/yr, Takeda Pharmaceutical (TAK) +7.5%/yr, Bristol Myers Squibb (BMY) +0.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bristol Myers Squibb (BMY) has the highest dividend yield: Takeda Pharmaceutical (TAK) 1.54%, Bristol Myers Squibb (BMY) 4.16%. Aurinia Pharmaceuticals (AUPH) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Takeda Pharmaceutical (TAK) has been the steadiest (Aurinia Pharmaceuticals (AUPH) 37.2%, Takeda Pharmaceutical (TAK) 21.5%, Bristol Myers Squibb (BMY) 28.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AUPH, TAK and BMY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Takeda Pharmaceutical (TAK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.